Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carsten Kobe

Showing results (61-70 of 152) with videos related to

Pageof 16
Sort By:
Clinical Nuclear Medicine|October 3, 2012
Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinibDeniz Kahraman, Arne Holstein, Matthias Scheffler, et al.
Leukemia & Lymphoma|July 12, 2011
Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisoneJana Markova, Deniz Kahraman, Carsten Kobe, et al.
Molecular Imaging and Biology|October 2, 2020
[<sup>18</sup>F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate CancerFelix Dietlein, Peter Mueller, Carsten Kobe, et al.
International Journal of Radiation Oncology, Biology, Physics|August 14, 2021
Involved-Field Radiation Therapy Prevents Recurrences in the Early Stages of Hodgkin Lymphoma in PET-Negative Patients After ABVD Chemotherapy: Relapse Analysis of GHSG Phase 3 HD16 TrialChristian Baues, Helen Goergen, Michael Fuchs, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 8, 2018
Does PET Reconstruction Method Affect Deauville Scoring in Lymphoma Patients?Ronald Boellaard, Carsten Kobe, Josée M Zijlstra, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|August 16, 2023
Dual-tracer PET/CT protocol with [<sup>18</sup>F]FDG and [<sup>68</sup>Ga]Ga-FAPI-46 outperforms single-tracer PET/CT with [<sup>18</sup>F]FDG in different cancer types, resulting in larger functional and gross tumor volumeSimone Wegen, Jasmin Weindler, Conrad-Amadeus Voltin, et al.
Plos One|December 21, 2018
Uptake in non-affected bone tissue does not differ between [18F]-DCFPyL and [68Ga]-HBED-CC PSMA PET/CTJochen Hammes, Melanie Hohberg, Philipp Täger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 11, 2025
Association between metabolic tumor burden and health-related quality of life in patients with classic Hodgkin lymphomaMarie Lommen, Jasmin J Weindler, Janina Jablonski, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 30, 2021
An <sup>89</sup>Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer PatientsFelix Dietlein, Carsten Kobe, Sergio Muñoz Vázquez, et al.
Blood|September 1, 2018
Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphomaCarsten Kobe, Helen Goergen, Christian Baues, et al.
Pageof 16

Showing results (61-70 of 152) with videos related to

Sort By:
Pageof 16
Clinical Nuclear Medicine|October 3, 2012
Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinibDeniz Kahraman, Arne Holstein, Matthias Scheffler, et al.
Leukemia & Lymphoma|July 12, 2011
Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisoneJana Markova, Deniz Kahraman, Carsten Kobe, et al.
Molecular Imaging and Biology|October 2, 2020
[<sup>18</sup>F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate CancerFelix Dietlein, Peter Mueller, Carsten Kobe, et al.
International Journal of Radiation Oncology, Biology, Physics|August 14, 2021
Involved-Field Radiation Therapy Prevents Recurrences in the Early Stages of Hodgkin Lymphoma in PET-Negative Patients After ABVD Chemotherapy: Relapse Analysis of GHSG Phase 3 HD16 TrialChristian Baues, Helen Goergen, Michael Fuchs, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 8, 2018
Does PET Reconstruction Method Affect Deauville Scoring in Lymphoma Patients?Ronald Boellaard, Carsten Kobe, Josée M Zijlstra, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|August 16, 2023
Dual-tracer PET/CT protocol with [<sup>18</sup>F]FDG and [<sup>68</sup>Ga]Ga-FAPI-46 outperforms single-tracer PET/CT with [<sup>18</sup>F]FDG in different cancer types, resulting in larger functional and gross tumor volumeSimone Wegen, Jasmin Weindler, Conrad-Amadeus Voltin, et al.
Plos One|December 21, 2018
Uptake in non-affected bone tissue does not differ between [18F]-DCFPyL and [68Ga]-HBED-CC PSMA PET/CTJochen Hammes, Melanie Hohberg, Philipp Täger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 11, 2025
Association between metabolic tumor burden and health-related quality of life in patients with classic Hodgkin lymphomaMarie Lommen, Jasmin J Weindler, Janina Jablonski, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 30, 2021
An <sup>89</sup>Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer PatientsFelix Dietlein, Carsten Kobe, Sergio Muñoz Vázquez, et al.
Blood|September 1, 2018
Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphomaCarsten Kobe, Helen Goergen, Christian Baues, et al.
Pageof 16